drug
lemborexant
Marketedupdated 5mo agoby Eisai Co Ltd
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying lemborexant
- phase4Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease
- phase2DORA and LP in Alzheimer's Disease Biomarkers
- phase2A Study to Assess the Pharmacodynamics of Lemborexant in Korean Participants With Insomnia Disorder
- phase4Lemborexant in Delayed Sleep Phase Syndrome
- phase2Lemborexant to Prevent Post-operative Delirium in Cardiac Surgery Patients
- phase3A Study of Lemborexant in Chinese Participants With Insomnia Disorder
- phase3Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1)
- phase2Acute Effect of Lemborexant on CSF Amyloid-Beta and Tau
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 20, 2031
~5.0 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (8)
- Oct 21, 2035formulationUS 10188652
- Oct 21, 2035formulationUS 10188652
- Oct 21, 2035formulationUS 10702529
- Oct 21, 2035formulationUS 10702529
- Oct 21, 2035formulationUS 11026944
- Oct 21, 2035formulationUS 11026944
- Sep 20, 2031compositionUS 82688485.0y
- Sep 20, 2031compositionUS 82688485.0y
FDA exclusivities (2)
- Apr 20, 2026M-293Method (3y)
- Apr 20, 2026M-293Method (3y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that